Does the FCM-NP platform support personalized neoantigens?

Yes. FCM-NPs extracted from a patient's own tumor naturally capture the full somatic mutation landscape, providing a comprehensive, multivalent personalized vaccine solution.

Preclinical Tumor-APC Fusion Platform for Cancer Vaccines

Q: Can you customize the fusion platform for specific tumor types?

Yes, our platform is modular. We can isolate membranes from any tumor cell line or biopsy and customize the nanoparticle core with specific adjuvants or inhibitors tailored for the target microenvironment.

Q: How do you verify the orientation of the membrane wrapping?

We use immunogold labeling and flow cytometry targeting extracellular epitopes like CD80 or CD86. High recovery confirms 'right-side-out' orientation, essential for host APC interaction.

Q: What preclinical readouts are provided for immune activation?

We provide data on DC maturation, MHC complex quantification, antigen-specific T-cell expansion (ELISpot), cytokine signatures, and longitudinal tumor growth inhibition.

Redefining whole-cell immunogenicity through "Nanomization" and cell membrane engineering. Creative Biolabs offers an innovative preclinical platform for the development of fusion cell membrane nano-vaccines (FCM-NPs).

Our solution bridges the gap between the complex antigen spectrum of tumor cells and the robust priming capacity of antigen presenting cells (APCs). By utilizing hybrid cell membrane technology, we help you create standardized, highly stable synthetic vaccines that deliver a broad repertoire of tumor-specific antigens directly to the immune system.

Consult Preclinical Experts

Overcoming Traditional Cell Fusion Barriers via FCM-NPs

While whole-cell fusion (DC-Tumor) provides a comprehensive antigen pool, its preclinical development is often hindered by high variability and poor stability. Our "Nano-Fusion" approach offers three unique advantages:

▶ Standardized Synthetic Workflow: Replacing live cell products with "cell-free" hybrid membranes ensures batch-to-batch consistency and ease of characterization.
▶ Broad Antigen Repertoire: FCM-NPs retain the full membrane protein profile of the tumor cell, including neoantigens and TAAs, while displaying APC-derived costimulatory molecules (CD80/86/40).
▶ Synergistic Adjuvant Loading: The core of the nanoparticle (e.g., PLGA) can be loaded with potent adjuvants like CpG-ODN, ensuring simultaneous antigen delivery and innate activation.

Specialized Preclinical Development Solutions

We provide a fully integrated pipeline to engineer and validate next-generation fusion nano-vaccines:

Hybrid Membrane Engineering

Strategic fusion of tumor cell membranes with DC or macrophage membranes. Optimization of fusion ratios to maximize antigen density and costimulatory signaling.

PLGA-Nano Encapsulation

Precise wrapping of hybrid membranes onto adjuvant-loaded PLGA cores. Ensuring uniform size distribution and high colloidal stability for preclinical dosing.

Immunogenic Characterization

Quantitative analysis of membrane orientation, protein recovery, and MHC complex retention. Verification of TLR9 activation and APC uptake in vitro.

In Vivo Protective Efficacy

Tracking tumor growth kinetics and metastasis inhibition in syngeneic models (e.g., Ovarian Cancer, Melanoma). Detailed immune profiling of T-cell infiltration.

Featured Preclinical Focus Areas

Harnessing FCM-NP technology to solve the most challenging barriers in oncology research:

Ovarian Cancer Immunotherapy

Utilizing DC/Ovarian cancer fusion membranes to target highly metastatic niches and overcome the immunosuppressive peritoneal microenvironment.

Explore Ovarian Models →

Neoantigen-Rich Hybrid Platforms

Engineering fusion vaccines derived from patient-specific tumor biopsies to capture the full landscape of somatic mutations for precision priming.

View Neoantigen Logic →

Cold Tumor Transformation

Leveraging FCM-NPs to recruit effector T cells into "immune deserts" and synchronize with checkpoint blockade for enhanced therapeutic windows.

Learn About TME Reversal →

"Off-the-Shelf" Cell-Free Designs

Developing standardized membrane-nanoparticle prototypes that maintain long-term bioactivity without the need for live cell logistics.

Get Prototype Details →

Agile Preclinical FCM-NP Development Pipeline

Our systematic workflow ensures the transition from biological fusion to a validated nano-vaccine candidate:

Step 1: Cell Selection & Fusion Design

Activities: Selecting appropriate tumor cell lines (e.g., SK-OV-3) and APC sources (e.g., BMDCs). Optimization of the cell-to-cell fusion ratio and bioinformatic assessment of key membrane biomarkers (MHC I/II, CD80).

Outcome: Optimal fusion blueprints optimized for antigen presentation.

Step 2: Fusion Cell Membrane (FCM) Extraction

Activities: Using customized lysis-extrusion or PEG-mediated fusion protocols to isolate the hybrid cell membranes. We perform high-purity isolation via differential centrifugation to ensure removal of nuclear components while retaining the membrane lipid-protein matrix.

Outcome: Characterized, high-purity hybrid membrane stocks.

Step 3: Nanoparticle Assembly & Adjuvant Loading

Activities: Synthesis of the PLGA core loaded with CpG-ODN. Wrapping of the adjuvant-core with the FCM using ultrasonic or mechanical extrusion methods. We optimize the zeta potential and particle size (~100-200 nm) to maximize lymphatic drainage.

Outcome: Standardized FCM-NP candidates with confirmed size and stability.

Step 4: Functional Mechanism & In Vitro Assays

Activities: Evaluating FCM-NP uptake by host DCs via confocal microscopy. We measure APC maturation signatures and assess the cross-presentation efficiency of tumor antigens to prime CD8+ T cells in co-culture systems.

Outcome: Functional proof-of-concept data for APC targeting and activation.

Step 5: In Vivo Efficacy & Immune Landscape Mapping

Activities: Testing in syngeneic murine models to quantify tumor growth inhibition and prevention of metastasis. We utilize spatial transcriptomics and flow cytometry to map the "Cold-to-Hot" transition of the TME following vaccination.

Outcome: Final preclinical data report supporting lead candidate selection.

Discuss Your Project Timeline

Proprietary Nano-Fusion Technology Platforms

Our solutions are powered by industry-leading systems tailored for complex membrane therapeutics:

FCM-NanoHub Core: A specialized platform for the precision synthesis of FCM-NPs. It ensures that the hybrid membranes are wrapped in a "right-side-out" orientation, which is critical for the accessibility of tumor antigens and costimulatory ligands to host immune cells.

Automated membrane extrusion systems
Validated protocols for diverse tumor-APC combinations
High-throughput adjuvant-loading optimization

Hybrid-Synapse Analytical Suite: A robust analytical platform designed to verify the molecular integrity of the fused membranes. We utilize high-resolution mass spectrometry and proteomics to confirm the presence and functionality of key immune complexes.

Quantitative MHC complex profiling
Validation of costimulatory molecule density
Longitudinal stability assays in physiological buffers

TME-Infiltrator Mapper: A specialized immunological suite designed to assess the infiltration and activation of TILs (Tumor Infiltrating Lymphocytes) induced by nano-fusion vaccines in preclinical models.

Multiplex IF for T-cell subset tracking (TEM, TRM)
Assessment of immunosuppressive factor depletion (MDSCs, Tregs)
Cytokine signature mapping via immunoassay experiments

FCM-NanoHub

Hybrid-Synapse

TME-Infiltrator

Scientific Case Study: FCM-NPs for Ovarian Cancer

Targeting Metastasis via Nano-Fusion Vaccines

Discovery: Research published in Frontiers in Immunology highlights a breakthrough in "cell-free" fusion vaccines. By wrapping hybrid DC/Tumor membranes onto PLGA nanoparticles, researchers created a potent FCM-NP platform for treating ovarian cancer.

Research Highlights:

Technical Mechanism: PLGA cores loaded with CpG-ODN were encapsulated with fusion membranes, ensuring simultaneous delivery of multiple antigens and adjuvants.
Industrial Significance: This "nanomization" strategy solves the complexity and instability issues of traditional live-cell fusion vaccines, enabling standardized production.
Outcome: The nano-vaccine significantly delayed tumor growth and metastasis in ovarian cancer murine models, demonstrating the immense potential for treating solid tumors.

In vivo immune activation evaluation of FCM-NPs in mice.

Fig.1 In vivo immune activation of FCM-NPs.^1,2

Frequently Asked Questions

Q: What is the main advantage of FCM-NPs over traditional live DC-Tumor fusion vaccines?

A: The primary advantage is standardization and stability. FCM-NPs are "cell-free" synthetic constructs. This eliminates the risks associated with live cell injection (e.g., poor survival, uncontrolled behavior) and allows for a standardized manufacturing process with clear quality control readouts for preclinical studies.

Q: Can you customize the fusion platform for specific tumor types, such as glioblastoma?

A: Yes. Our platform is highly modular. We can isolate membranes from any tumor cell line or primary biopsy and fuse them with host-derived APC membranes. We can further customize the nanoparticle core to carry specific adjuvants or inhibitors tailored for the glioblastoma microenvironment.

Q: How do you verify the orientation of the membrane wrapping on the nanoparticle?

A: We utilize immunogold labeling and flow cytometry with antibodies targeting extracellular epitopes (e.g., CD80, CD86, or specific TAAs). A high recovery of these extracellular markers confirms the "right-side-out" orientation, which is essential for efficient APC interaction.

Q: Does the FCM-NP platform support the delivery of personalized neoantigens?

A: Absolutely. By using membranes extracted from a patient’s own tumor tissue, the FCM-NPs naturally capture the full repertoire of somatic mutations (neoantigens). This provides a comprehensive, multivalent personalized vaccine solution without the need for individual peptide synthesis.

Q: What preclinical readouts are provided for immune activation?

A: We provide high-resolution data including DC maturation phenotyping, MHC complex quantification, antigen-specific T-cell expansion (ELISpot), cytokine secretion (IFN-γ/IL-12), and longitudinal tumor growth inhibition curves in animal models.

Related Resources

References:
1. Zhang, Lei, et al. "Development of a dendritic cell/tumor cell fusion cell membrane nano-vaccine for the treatment of ovarian cancer." Frontiers in Immunology 13 (2022): 828263.
2. Distributed under Open Access License CC BY 4.0, without modification.